Troutman Pepper Advises PharmaCyte Biotech on Follow-On Public Offering and Uplisting to Nasdaq

NEW YORK – Troutman Pepper client PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, recently closed its underwritten public offering of approximately $15 million and completed its uplisting to Nasdaq. Read a company press release about the closing.

PharmaCyte’s proprietary cellulose-based live cell encapsulation technology, Cell-in-a-Box^®, supports the development of therapies for several types of cancer and diabetes. The company’s product candidate for cancer involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active or “cancer-killing” form. The product candidate for Type 1 diabetes and insulin-dependent Type 2 diabetes involves encapsulating a human liver cell line that has been genetically engineered to produce and release insulin in response to the levels of blood sugar in the human body.

A team of Troutman Pepper attorneys, led by Partner Merrill Kraines and Counsel Todd Kornfeld, assisted PharmaCyte throughout its uplisting and public offering. Other Troutman Pepper attorneys included Partners Robert Friedel, Judy O’Grady and Nicole Stakleff; Associates Roe Granger and Dean Longfield; and Attorneys Christina Boston and Noreen Onimus.

Health sciences is a core practice at Troutman Pepper. The firm has more than 150 attorneys who represent clients such as innovative biotech, pharmaceutical, and medical device developers and manufacturers; physicians, hospitals, and other health care providers; health insurers and other payors; and a wide range of members of the health care supply chain.

About Troutman Pepper
Troutman Pepper is a national law firm with more than 1,200 attorneys strategically located in 23 U.S. cities. The firm’s litigation, transactional, and regulatory practices advise a diverse client base, from start-ups to multinational enterprises. The firm provides sophisticated legal solutions to clients’ most pressing business challenges, with depth across industry sectors, including construction, energy, finance, health sciences, insurance, private equity, real estate, and technology, among others. Learn more at troutman.com.